Effects of Cycle Therapy With Romosozumab and Denosumab 2 Years vs 1 Year Romosozumab Followed by 1 Year Denosumab in Postmenopausal Osteoporosis Patients-A Randomized Control Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a traditional sequential treatment regimen (12 months of Romosozumab followed by 12 months of Denosumab). The goal is to determine which approach yields better therapeutic outcomes and to optimize drug strategies for osteoporosis patients.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 50
Maximum Age: 90
Healthy Volunteers: f
View:
• 1\. Postmenopausal women aged 50-90 years
• 2\. BMD T-score ≤ -3.0 at any lumbar vertebra
• 3\. Physically and mentally capable of understanding and complying with the study protocol and follow-up
• 4\. Signed informed consent
Locations
Other Locations
Taiwan
National Taiwan University Hospital
RECRUITING
Taipei
Contact Information
Primary
Fon-Yih Tsuang
k880113a@gmail.com
886-2312-3456
Time Frame
Start Date: 2025-04-08
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 70
Treatments
Active_comparator: Sequential therapy group
Romosozumab followed by Denosumab
Experimental: Cycle therapy group
Romosozumab and Denosumab Cycle Therapy
Related Therapeutic Areas
Sponsors
Leads: National Taiwan University Hospital